tradingkey.logo
搜索

Charles River Laboratories International Inc

CRL
添加自选
234.800USD
-5.630-2.34%
收盘 07-29 16:00美东报价延迟15分钟
11.31B总市值
亏损市盈率 TTM

Charles River Laboratories International Inc

234.800
-5.630-2.34%

关于 Charles River Laboratories International Inc 公司

Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.

Charles River Laboratories International Inc简介

公司代码CRL
公司名称Charles River Laboratories International Inc
上市日期Jun 23, 2000
CEOFoster (James C)
员工数量18600
证券类型Ordinary Share
年结日Jun 23
公司地址251 Ballardvale St
城市WILMINGTON
上市交易所NASDAQ OMX NASDAQ Basic NYSE
国家United States of America
邮编01887
电话17812226000
网址https://www.criver.com/
公司代码CRL
上市日期Jun 23, 2000
CEOFoster (James C)

Charles River Laboratories International Inc公司高管

名称
名称/职务
职务
持股
持股变动
Ms. Birgit Girshick
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
58.79K
-5.76%
Mr. James C. Foster
Mr. James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
26.98K
-920.54%
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
20.94K
+19.00%
Mr. Joseph W. LaPlume
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
14.72K
+26.15%
Ms. Shannon M. Parisotto
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment Management
Corporate Executive Vice President - Discovery and Safety Assessment Management
10.72K
-14.26%
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Independent Director
6.35K
+22.65%
Ms. Reshema Kemps-Polanco
Ms. Reshema Kemps-Polanco
Independent Director
Independent Director
4.56K
+43.24%
Dr. Craig B. Thompson, M.D.
Dr. Craig B. Thompson, M.D.
Independent Director
Independent Director
3.85K
+37.34%
Mr. Abraham N. (Abe) Ceesay
Mr. Abraham N. (Abe) Ceesay
Independent Director
Independent Director
2.38K
+60.32%
Mr. Paul W. Graves
Mr. Paul W. Graves
Independent Director
Independent Director
2.38K
+60.32%
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Birgit Girshick
Ms. Birgit Girshick
Chief Operating Officer, Corporate Executive Vice President
Chief Operating Officer, Corporate Executive Vice President
58.79K
-5.76%
Mr. James C. Foster
Mr. James C. Foster
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
26.98K
-920.54%
Ms. Victoria L. (Vicky) Creamer
Ms. Victoria L. (Vicky) Creamer
Corporate Executive Vice President, Chief People Officer
Corporate Executive Vice President, Chief People Officer
20.94K
+19.00%
Mr. Joseph W. LaPlume
Mr. Joseph W. LaPlume
Corporate Executive Vice President - Corporate Development and Strategy
Corporate Executive Vice President - Corporate Development and Strategy
14.72K
+26.15%
Ms. Shannon M. Parisotto
Ms. Shannon M. Parisotto
Corporate Executive Vice President - Discovery and Safety Assessment Management
Corporate Executive Vice President - Discovery and Safety Assessment Management
10.72K
-14.26%
Ms. Virginia M. (Gina) Wilson, CPA
Ms. Virginia M. (Gina) Wilson, CPA
Independent Director
Independent Director
6.35K
+22.65%

常见问题

Charles River Laboratories International Inc的前五大股东是谁?

Charles River Laboratories International Inc 的前五大股东如下:Ms. Birgit Girshick

有多少机构持有Charles River Laboratories International Inc(CRL)的股份?

截至2026Q1,共有1429家机构持有Charles River Laboratories International Inc的股份,合计持有的股份价值约为56.13M,占公司总股份的116.51%。与2025Q4相比,机构持股有所增加,增幅为-7963916.00。

哪个业务部门对Charles River Laboratories International Inc的收入贡献最大?

在2026Q1,DSA业务部门对Charles River Laboratories International Inc的收入贡献最大,创收2.40B,占总收入的59.84%。
tradingkey.logo
风险提示:我们的网站和移动应用程序仅提供关于某些投资产品的一般信息。Finsights 不提供财务建议或对任何投资产品的推荐,且提供此类信息不应被解释为 Finsights 提供财务建议或推荐。
投资产品存在重大投资风险,包括可能损失投资的本金,且可能并不适合所有人。投资产品的过去表现并不代表其未来表现。
Finsights 可能允许第三方广告商或关联公司在我们的网站或移动应用程序的任何部分放置或投放广告,并可能根据您与广告的互动情况获得报酬。
© 版权所有: FINSIGHTS MEDIA PTE. LTD. 版权所有